Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene and Juno partner in CART/TCR deal worth $1bn up front

Executive Summary

Celgene Corp. and Juno Therapeutics Inc. entered into a major ten-year alliance that sees both partners benefiting from the other’s immunotherapeutics expertise, with an initial focus on T-cell receptor (TCR)- and chimeric antigen receptor T-cell (CART)-based treatments for cancer and autoimmune diseases.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register